Arranta Bio Announces Key Leadership Additions As It Commits to a $100M Investment in Building End-to-End Microbiome Capacity (BioSpace)

Arranta Bio Announces Key Leadership Additions As It Commits to a $100M Investment in Building End-to-End Microbiome Capacity

Arranta Bio, the leading microbiome contract development and manufacturing organization (CDMO), announced the strengthening of its senior leadership team with the addition of David Stevens as Chief Operations Officer and Jason Rahal as Senior Vice President of Business Development. Arranta has committed $100M to build end-to-end capacity as the first dedicated microbiome CDMO.

Arranta Bio acquired UF Innovate | The Hub resident client CaptozymeTM, now Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for secondary hyperoxaluria.

Learn more about Arranta Bio Announces Key Leadership Additions As It Commits to a $100M Investment in Building End-to-End Microbiome Capacity.
X